Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Midatech Pharma starts testing on childhood tumours

Midatech announced on International Rare Disease Day 2016 it has commenced dosing of its MTX110 treatment for DIPG.
Midatech Pharma starts testing on childhood tumours
Midatech is heavily committed to making treatment a reality for rare disease patients

Midatech Pharma (LON:MTPH, NASDAQ:MTP) has drawn attention to International Rare Disease Day and the company's research into potential cures for ultra-rare diseases.

Midatech is heavily committed to making treatment a reality for rare disease patients with crucial unmet need and has recently commenced dosing of its MTX110 treatment for diffuse intrinsic pontine glioma (DIPG), an ultra-rare and currently fatal childhood brain tumour, on a named patient basis through leading neuro-surgery and paediatric oncology practitioners in Bristol, a treatment for which compassionate use requests are rapidly emerging.

"One of the focus areas of our current development strategy is oncology and we are pleased to be able to announce that we have commenced dosing of our MTX110 treatment for DIPG, an ultra-rare childhood tumour, on International Rare Disease Day 2016,” said Dr Jim Phillips, chief executive officer of Midatech.

“We are committed to helping rare disease patients where there is a high unmet need, including those with the ultra-rare condition DIPG. The lack of treatment alternatives for this condition coupled with our recent clinical-use advances means we are optimistic about seeing a fast-tracked product reach the market in the near future for the benefit of these patients," he added.

Shares in Midatech fell 0.2% to 170.2p in the first hour of trading in a market that was off 0.9%.

 

John-H.jpg
Why Invest In Midatech Pharma Plc? Read More Here

Register here to be notified of future MTPH Company articles
View full MTPH profile

Midatech Pharma Plc Timeline

Big Picture
November 22 2016

Related Articles

GW_Pharma.png
November 22 2016
With the balance sheet now significantly strengthened, we anticipate the company is well-positioned to capture value in areas where its technology platforms offer material improvements for patient care - Panmure Gordon.
picture of drug lab
November 07 2016
The aim is for clinical trials for AP102 to start next year

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.